Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 7:2022:9432410.
doi: 10.1155/2022/9432410. eCollection 2022.

Might Patients with Metastatic Gastrointestinal Stromal Tumors Benefit from Operative Management? A Population-Based Retrospective Study

Lei Yue  1 , Yingchao Sun  1 , Mengjia Hu  2 , Weiling Hu  1   3
Affiliations

Might Patients with Metastatic Gastrointestinal Stromal Tumors Benefit from Operative Management? A Population-Based Retrospective Study

Lei Yue et al. Biomed Res Int. .

Retraction in

Abstract

Background: With respect to effect of surgery on the therapy of patients with metastatic gastrointestinal stromal tumors (mGISTs), still no consensus has been reached. This research designed to investigate the effect of surgical treatment on prognosis in patients with mGISTs.

Methods: The population-based study consisted of 6282 GIST patients diagnosed between 2001 and 2016, from the Surveillance, Epidemiology, and End Results (SEER) database registry. The Kaplan-Meier method and Cox model were employed for the exploration of the effect of surgery on overall survival (OS) and GIST-specific survival (GSS).

Results: In total, 6282 patients were diagnosed with GISTs, including 1238 (19.7%) mGIST patients and 5044 (80.3%) non-mGIST patients. Compared with the patients with non-mGISTs, metastatic patients assumed relatively lower proportion of surgical management (756 [61.1%] vs. 4666 [92.5%], P < 0.001). Based on unadjusted analysis, mGIST patients with operative management presented higher five years OS together with GSS in comparison with those without operative management (OS: 58.3% vs. 33.1%, P < 0.001; GSS: 61.6% vs. 36.7%, P < 0.001). Multivariable analysis found that no surgery was correlated to more than 2-fold increased death risk (OS, adjusted HR = 2.27, 95% CI: 1.90-2.71; GSS, adjusted HR = 2.42, 95% CI: 2.00-2.93).

Conclusion: Metastatic GIST patients could potentially benefit from operative management with improved GSS and OS.

PubMed Disclaimer

Conflict of interest statement

All authors have no competing financial interests to state.

Figures

Figure 1
Figure 1
Flow diagram of the criteria of patients' selection.
Figure 2
Figure 2
GIST-specific survival among mGIST patients with surgery management and those without surgery management.
Figure 3
Figure 3
GIST-specific survival among mGIST patients with different tumor sizes stratified by surgery management.
Figure 4
Figure 4
GIST-specific survival among mGIST patients with different tumor sites stratified by surgery management.
Figure 5
Figure 5
(a) mGIST overall survival nomogram. The calibration curve was used for the forecast of patient's survival at (b) 3 years and (c) 5 years in the modeling group and at (d) 3 years and (e) 5 years in the validation group.
See this image and copyright information in PMC

References

    1. Sepe P. S., Brugge W. R. A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nature Reviews Gastroenterology & Hepatology . 2009;6(6):363–371. doi: 10.1038/nrgastro.2009.43. - DOI - PubMed
    1. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science . 1998;279(5350):577–580. doi: 10.1126/science.279.5350.577. - DOI - PubMed
    1. Hirota S., Ohashi A., Nishida T., et al. Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors. Gastroenterology . 2003;125(3):660–667. doi: 10.1016/S0016-5085(03)01046-1. - DOI - PubMed
    1. Heinrich M. C., Corless C. L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science . 2003;299(5607):708–710. doi: 10.1126/science.1079666. - DOI - PubMed
    1. Emile J. F., Brahimi S., Coindre J. M., et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Medical Oncology . 2012;29(3):1765–1772. doi: 10.1007/s12032-011-0074-y. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources